Table 1.
Tumor Characteristics and immune status in stage II-III colon carcinoma patient.
| Clinicopathological parameters | Total no. | CD8+ TILs | p value | Total no. | Tumor CD274/PD-L1 | p value | ||
|---|---|---|---|---|---|---|---|---|
| High | Low | High | Low | |||||
| 867 | 283 (33%) | 584 (67%) | 864 | 384 (44%) | 480 (56%) | |||
| Sex | 0.39 | 0.7 | ||||||
| Female | 401 (46%) | 125 (44%) | 276 (47%) | 401 (46%) | 181 (47%) | 220 (46%) | ||
| Male | 466 (54%) | 158 (56%) | 308 (53%) | 463 (54%) | 203 (53%) | 260 (54%) | ||
| Age | 0.16 | 0.59 | ||||||
| <65 | 387 (45%) | 136 (48%) | 251 (43%) | 385 (45%) | 175 (46%) | 210 (44%) | ||
| ≥65 | 480 (55%) | 147 (52%) | 333 (57%) | 479 (55%) | 209 (54%) | 270 (56%) | ||
| Tumor location | 0.02 | 0.68 | ||||||
| Proximal colon | 425 (49%) | 155 (55%) | 270 (46%) | 423 (49%) | 185 (48%) | 238 (50%) | ||
| Distal colon | 442 (51%) | 128 (45%) | 314 (54%) | 441 (51%) | 199 (52%) | 242 (50%) | ||
| pT stage | <0.0001* | 0.001* | ||||||
| Tis | 2 (0.2%) | 1 (0.4%) | 1 (0.2%) | 2 (0.2%) | 1 (0.3%) | 1 (0.2%) | ||
| pT1 | 3 (0.4%) | 0 (0%) | 3 (0.5%) | 3 (0.4%) | 2 (0.5%) | 1 (0.2%) | ||
| pT2 | 29 (3%) | 15 (5%) | 14 (2%) | 29 (3%) | 15 (4%) | 14 (3%) | ||
| pT3 | 701 (81%) | 239 (84%) | 462 (79%) | 698 (81%) | 311 (81%) | 387 (81%) | ||
| pT4 | 132 (15%) | 28 (10%) | 104 (18%) | 132(15%) | 55 (14%) | 77 (16%) | ||
| pN stage | <0.0001* | 0.85 | ||||||
| Negative | 457 (53%) | 176 (62%) | 281 (48%) | 456 (53%) | 204 (53%) | 252 (53%) | ||
| Positive | 410 (47%) | 107 (38%) | 303 (52%) | 408 (47%) | 180 (47%) | 228 (48%) | ||
| pathological TNM stage | <0.0001* | 0.85 | ||||||
| Stage II | 457 (53%) | 176 (62%) | 281 (48%) | 456 (53%) | 204 (53%) | 252 (53%) | ||
| Stage III | 410 (47%) | 107 (38%) | 303 (52%) | 408 (47%) | 180 (47%) | 228 (48%) | ||
| Tumor differentiation | <0.0001* | 0.02 | ||||||
| Well to moderate | 734 (85%) | 217 (77%) | 517 (89%) | 732 (85%) | 313 (82%) | 419 (87%) | ||
| Poor | 121 (14%) | 63 (22%) | 58 (10%) | 120 (14%) | 65 (17%) | 55 (11%) | ||
| Unknown | 12 (1%) | 3 (1%) | 9 (2%) | 12 (1%) | 6 (2%) | 6 (1%) | ||
| Lymphovascular invasion (LVI) | 0.3103 | 0.3034 | ||||||
| Absent | 421 (49%) | 144 (51%) | 277 (47%) | 419 (48%) | 194 (51%) | 225 (47%) | ||
| Present | 441(50%) | 137 (48%) | 304 (52%) | 440 (51%) | 188 (49%) | 252 (52%) | ||
| Unknown | 5 (1%) | 2 (1%) | 3 (1%) | 5 (1%) | 2 (1%) | 3(1%) | ||
| Perineural Invasion (PNI) | <0.0001* | 0.0195 | ||||||
| Absent | 534 (62%) | 203 (72%) | 331 (57%) | 533 (62%) | 221 (57%) | 312 (65%) | ||
| Present | 326 (%) | 78 (27%) | 248 (42%) | 324 (37%) | 161 (42%) | 163 (34%) | ||
| Unknown | 7 (1%) | 2 (1%) | 5 (1%) | 7 (1%) | 2 (1%) | 5 (1%) | ||
| MMR status | <0.0001* | 0.14 | ||||||
| MMR-proficient | 795 (92%) | 245 (87%) | 550 (94%) | 794 (92%) | 347 (90%) | 447 (93%) | ||
| MMR-deficient | 68 (8%) | 38 (13%) | 30 (5%) | 68 (8%) | 36 (9%) | 32 (7%) | ||
| NA | 4 (0%) | 0 (0%) | 4 (1%) | 2 (0.2%) | 1 (0.3%) | 1 (0.2%) | ||
NA: not available. Fisher’s exact test was used when >25% of the cells have expected counts less than 5. The Pearson’s chi-square and Fisher’s exact test did not include the “NA” and “unknown” group. *p < 0.005 is significant and 0.005 < p < 0.05 is suggestive evidence.